Endocrine Abstracts

Case history: A 53-year-old male with melanoma who had a previous surgical excision of his skin lesion in December 2018 was being treated with adjuvant pembrolizumab. In June 2019 his treatment changed to combination immune checkpoint inhibitor therapy (ICPi) with ipilimumab and nivolumab due to radiological recurrence.Investigations: There were no pre-ICPi endocrine investigations available. In July 2019, thyroid function tests (TFTs) showed thyroid-sti...

Acromegaly causes impaired insulin sensitivity and reduced fat mass. Using acipimox to block lipolysis, the impact of free fatty acids (FFA) on insulin sensitivity in active acromegaly was investigated. 1H MRS was used to quantify triglyceride (TG) content of liver and muscle.Methods: 6 patients with active acromegaly (AA) (5M, age 59 (34–70), IGF-I (ng/ml) (median (range)) (452 (342–1002)) were studied on 2 visits; (i) baseline (BL)...

Introduction: Patients with pituitary deficiencies suffer from impaired quality of life regardless of substitution therapy with hydrocortisone, thyroxine (T4), sex hormones or GH. Central hypothyroidism (CH) is difficult to diagnose and treat because symptoms are non-specific and TSH-levels cannot be used for assessment. There is no consensus for the fT4-goal of thyroxine-replacement in patients with CH.Aim: To determine the impact ...

Background: Bone toxicity and more specifically Radiotherapy Related Insufficiency Fractures (RRIFs) are common late effects of pelvic radiotherapy, associated with increased morbidity and reduced quality of life, while their cost to the health system is currently unknown. The mechanisms underlying RRIFs are not well understood. Effective preventive techniques and management pathways need to be developed and validated with robust clinical and health economic analyses. The RadB...

Gigantism is an extremely rare condition and hence the relevant literature is largely a series of case reports. We present data on patients with gigantism <20 years of age identified from Pfizer’s Acrostudy registry of patients treated with pegvisomant.Eleven patients (5M) were identified: IGF1 at diagnosis was 1.6×ULN (1.15–3.3), height +5 SDS (1.1–3.8) and age 14.5 years (4–19). The three youngest (4, 7 and 14 years) had pi...